DIAGNOS (CVE:ADK) Stock Price Down 5.4% – Should You Sell?

DIAGNOS Inc. (CVE:ADK) shares were down 5.4% during mid-day trading on Monday. The stock traded as low as C$0.34 and last traded at C$0.35. 187,338 shares were traded during mid-day trading, a decline of 18% from the average daily volume of 229,610 shares. The stock had previously closed at C$0.37.

DIAGNOS Stock Performance

The firm’s 50 day moving average is C$0.45 and its 200-day moving average is C$0.31. The stock has a market capitalization of C$42.36 million, a price-to-earnings ratio of -8.75 and a beta of 0.40. The company has a debt-to-equity ratio of 204.05, a quick ratio of 0.68 and a current ratio of 1.49.

Insiders Place Their Bets

In other news, Director Robert Dunn acquired 200,000 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was acquired at an average price of C$0.30 per share, for a total transaction of C$60,000.00. Following the completion of the transaction, the director owned 2,117,778 shares in the company, valued at approximately C$635,333.40. The trade was a 10.43% increase in their position. Insiders have acquired a total of 433,571 shares of company stock valued at $146,400 over the last three months. 16.81% of the stock is currently owned by insiders.

DIAGNOS Company Profile

DIAGNOS Inc provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.